LAVI Ltd
Nov 2011

May 2011
For the first time an Israeli public medical facility offers Vidion treatment for chronic AMD patients.
The treatment is delivered to patients at Tel Aviv Sorasky Medical Center.



Dec. 2010
Nara Hospital has begun treating WET Age realated Macular Degenration with the VIDION technology offering hope for chronic patients
.


Oct. 2010
 
July 2010

1. In a phase III study trial reported on June 21st in the Journal of Clinical Oncology,46 patients were  
   enrolled in a randomized study to protracted fluorouracil infusion on days 1 through 14 every 3 weeks
   with or without hepatic intra-arterial injection of SIR-Spheres®. With a median follow-up of 2 years the
   results are as follows:

   • The median time to liver progression was 5.5 months compared to 2.1 months  
      in the control group.
   • The toxicity rate was lower in the study group, compared to the control group.
   • Median overall survival was 10.0 months in the study group compared to 7.3 
     months in the control group.


2. SIR-Spheres® is registered in the Ministry Of Health (M.O.H) as a medical 
   device. The current license includes the USA + EU + Australian indications. This
   means that the SIR-Spheres® may be injected to 
   patients suffering from unresectable malignant tumors in the liver, either primary
   tumors such as Hepatoma or metastatic tumors from any origin.



Download a full pdf article
Top  |  Print